<DOC>
	<DOCNO>NCT00262678</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety sublingual fentanyl tablet relieve breakthrough pain cancer patient .</brief_summary>
	<brief_title>Efficacy Safety Sublingual Fentanyl Tablets Treatment Breakthrough Pain Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<criteria>Males females 17 year age older Stable cancerrelated pain . Are receive stable , fixedschedule oral opioid regimen equivalent 60 1000 mg oral morphine per day transdermal fentanyl therapy equivalent 50 300 Âµg/h , stable dose opioid medication relief breakthrough pain least 14 day prior screen . Experiencing 14 episode breakthrough pain per day . Meet criterion define Eastern Cooperative Oncology Group ( ECOG ) Performance Status Grade 0 , 1 , 2 . Are pregnant lactating . Have uncontrolled rapidly escalate pain . Have moderate severe ulcerative mucositis . Have cardiopulmonary disease would increase risk administer potent opioids . Have neurologic psychologic disease would compromise data collection Have clinically significant condition would , investigator 's opinion , preclude study participation . Are currently take monoamine oxidase inhibitor ( MAOIs ) , take MAOIs within 14 day prior enrol study . Have receive strontium 89 therapy within 60 day prior enter study . Have receive antineoplastic therapy within 2 week study entry , investigator 's opinion , influence assessment breakthrough pain Have receive investigational drug ( nonapproved ) within 30 day prior first dose study medication , schedule receive investigational drug EN3267 course study . Have hypersensitivity , allergy , contraindication fentanyl . Have significant prior history substance abuse alcohol abuse . May difficulty comply protocol , assess investigator .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>